RxDoctor Payments DataLook up a doctor →

Fred Defrancesch, MD

Physical Medicine & Rehabilitation · Metairie, LANPI 1558460261

Payments from drug & device makers

$10,573in general payments, 2019–2025

Across 480 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Vertiflex, Inc.$1K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$836
  • IBSA Pharma Inc.$460
  • Forte Bio-pharma LLC$455
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$1,71516%
  • Food & beverage$8,85984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,573 in reported general payments places this provider in the 95th percentile of 117 physical medicine & rehabilitation providers in Louisiana.

See all physical medicine & rehabilitation providers in Louisiana

Medicare billing

Part B allowed, 2024
$99,613
Medicare patients
143
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen350$116,047
Xtampza ErOxycodone Myristate67$46,013
BelbucaBuprenorphine Hcl33$28,607
OxycontinOxycodone Hcl20$26,942
GraliseGabapentin13$14,658
MovantikNaloxegol Oxalate27$11,475
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen219$4,650
Fentanyl23$4,385
Tramadol Hcl ErTramadol Hcl46$2,552
Morphine Sulfate ErMorphine Sulfate87$2,551
Lidocaine21$1,561
Tizanidine Hcl211$1,547
Gabapentin176$1,318
Oxycodone Hcl51$1,099
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine44$1,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$836$74,620100 claims
Almatica Pharma LLCGralise$208$14,65813 claims
Redhill Biopharma Inc.Movantik$49$11,47527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 physical medicine & rehabilitation providers in Louisiana.

Other physical medicine & rehabilitation in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →